Showing results (121-130 of 237) with videos related to

Sort By:
Pageof 24
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Blood|April 12, 2012
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationNicola Gökbuget, Daniel Stanze, Joachim Beck, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Blood|November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsGuido Bisping, Martin Kropff, Doris Wenning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Acta Haematologica|April 12, 2017
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center AnalysisGabriela B Thoennissen, Dennis Görlich, Ulrike Bacher, et al.
Blood Cancer Journal|May 2, 2024
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patientsAnn-Kristin Schmälter, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Pageof 24